{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-26-000073","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2026-08-13T20:02:19+00:00","discovered_at":"2026-08-13T20:03:01.103681+00:00","generated_at":"2026-08-13T20:03:15.122714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gossamer Q2 net income $16.9M; NDA on track Sept 2026; reacquires seralutinib rights","bullets":["Q2 2026 net income $16.9M vs net loss $38.3M in Q2 2025; revenue $9.2M from Chiesi collaboration.","NDA submission for seralutinib in PAH on track for Sept 2026; FDA feedback from Pre-NDA Type B meeting; potential approval decision Q3 2027.","Reacquired worldwide rights to seralutinib from Chiesi; no upfront cash, Chiesi gets capped royalty and milestone payments.","Exchanged $181.1M of 5.00% 2027 notes for $65.2M new 7.50% 2030 notes, reducing debt by ~$115.9M; 2027 notes now ~$18.9M.","Cash $57.0M at June 30, 2026; expected to fund operations into Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-26-000073","json":"https://secwatch.observer/filing/0001728117-26-000073.json","markdown":"https://secwatch.observer/filing/0001728117-26-000073.md","text":"https://secwatch.observer/filing/0001728117-26-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/0001728117-26-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/goss-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:03:15.122714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}